- Home
- DPG vs ALT Comparison
DPG vs ALT Comparison
Compare DPG & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DPG | ALT |
|---|---|---|
| Founded | N/A | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 464.9M | 415.3M |
| IPO Year | 2011 | 2005 |
Fundamental Metrics
Financial Performance| Metric | DPG | ALT |
|---|---|---|
| Price | $14.96 | $4.21 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $16.00 |
| AVG Volume (30 Days) | 114.0K | ★ 2.9M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 19.28 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $20,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $10.45 | $2.91 |
| 52 Week High | $14.90 | $7.73 |
Technical Indicators
Market Signals| Indicator | DPG | ALT |
|---|---|---|
| Relative Strength Index (RSI) | 80.05 | 37.95 |
| Support Level | $12.37 | $3.78 |
| Resistance Level | N/A | $4.25 |
| Average True Range (ATR) | 0.22 | 0.19 |
| MACD | 0.03 | -0.05 |
| Stochastic Oscillator | 93.00 | 6.62 |
Price Performance
Historical ComparisonAbout DPG Duff & Phelps Utility and Infrastructure Fund Inc.
Duff & Phelps Utility & Infrastructure Fund Inc. is an investment fund. Its investment objective is to seek total return, resulting from a high level of current income, with an emphasis on providing tax-advantaged dividend income.
About ALT Altimmune Inc.
Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.